OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
July 13, 2022
Merck, known as MSD outside the United States and Canada, now offers the Merck Digital Sciences Studio, designed to enable innovative tech for drug discovery and development.
July 08, 2022
Coya Therapeutics has secured intellectual property rights to the research, development, and manufacturing of exosome-polymer hybrids.
VeriSIM Life and Mayo Clinic are collaborating to develop new promising drug candidates.
NRG Therapeutics and Domainex aim to develop novel small-molecule drugs to treat neurodegenerative disorders, such as Parkinson’s disease.
LG Chem has decided to proceed with IND-enabling studies and has renewed a license with Avacta.
July 07, 2022
In this exclusive Drug Digest video, experts from Roche and MilliporeSigma divulge factors that could influence an organization to pursue specific biomolecules for development.
July 03, 2022
Biologics are forming a greater proportion of the development pipeline, but there are still some formulation difficulties to overcome to ensure clinical and commercial success.
Single-cell analytical technologies can deepen the understanding of cell biology and, therefore, disease mechanisms.
Lack of toxicity data and poor physicochemical properties must be overcome.
July 02, 2022
Pharma should expand on successful cell therapies in oncology by applying these development and manufacturing methods to neuronal cell therapies.